Test Overview
Clinical Utility
Lysozyme in the serum is primarily due to the degradation of granulocytes and monocytes and its concentration reflects the turnover of these cells. Increases are seen in benign and malignant processes. Serum lysozyme is elevated in patients with acute or chronic granulocytic or monocytic leukemias and levels decrease with successful treatment. Conversely, patients with lymphocytic leukemia may have depressed plasma lysozyme levels.
Method
Enzymatic
Result Included
Lysozyme (Muramidase)
Aliases/Synonyms
Muramidase
Specimen
Specimen Type
SerumContainers
Collection Containers
Gold top (clot activator & gel)
Volume
Sample Volume
1.0 mL
Minimum Volume
0.5 mL
Collection & Handling
Handling Information
Centrifuge serum specimens within 1 hour of collection. Delayed separation of the serum can result in spuriously high levels of lysozyme.
Stability
| Ambient | Refrigerated | Frozen |
|---|---|---|
| 24 hours | 15 days | 18 days |
Rejection Criteria
| Criteria | Specification |
|---|---|
| Hemolysis | Moderate to Gross |
| Lipemic | Gross |
Performance & Interpretation
Turnaround Time
10 days
Results
Name
Units
Reference Range
Conversion
-
Lysozymemcg/mL5.0 - 11.0
Referral Location
Out-of-Country
Interface & Setup
HL7 Interface Codes
| Order Code | Result Name | Result Codes | Units |
|---|---|---|---|
| LYSO | LYSOZYME (MURAMIDASE) | 62651 | mcg/mL |
Test Version
Last Updated
2025-11-19